Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.21. Hemispherx BioPharma shares last traded at $0.21, with a volume of 747,915 shares trading hands.
Hemispherx BioPharma Price Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than Hemispherx BioPharma
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Stocks Helping to Bring AI to Healthcare
- Transportation Stocks Investing
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- What is the NASDAQ Stock Exchange?
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
